A Phase 4 interventional study of Ropivacaine and Ropivacaine in Surgical Procedure, Unspecified and Pain, Postoperative, sponsored by Stanford University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-08.
Sponsored by Stanford University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 184 studies testing ropivacaine in Pain, Postoperative — 20 open to participants now, 22 under way, 2 of them phase 3. Ropivacaine · Pain, Postoperative.
Among the 184 studies testing ropivacaine in Pain, Postoperative, this one is the 5th largest by planned enrollment, is one of 12 that started in 2018, is one of 84 in phase 4, reaches primary completion later than 14 of the 21 other live ones, and was the 96th registered.
5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.
Browse Pain, Postoperative studies →20 of the 184 studies testing ropivacaine in Pain, Postoperative are open now, in 10 countries. Recruiting first, the newest first:
Maternity Hospital - State Budgetary Institution of the Rostov Region, Taganrog · Sites in Russia
Ages 18–40 · Women only
Huazhong University of Science and Technology · Sites in China
Ages 18–80
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
Mount Sinai Hospital, Canada · Sites in Canada
Ages 18+ · Women only · Healthy volunteers
TLC Biopharmaceuticals, Inc. · Sites in United States
Ages 18–70
By country, each count listing its studies:
Ropivacaine: first FDA approval 1996 (NAROPIN). What it is approved for, and how studies give it, is on its page →
Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
184 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 24 · Phase 4 84
First in 2003; this study’s year is marked. 12 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.
Median enrollment 70 across the 184 interventional studies. Of the 125 that completed or were terminated, 32 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 184 have an industry lead sponsor. The 10 most frequent:
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
25 studies in Pain, Postoperative by Stanford University: 8 open now, 8 under way, none of them phase 3. Of 13 finished, 5 (38%) have results posted.
Among the 25 studies in Pain, Postoperative by Stanford University, this one has the largest planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2018, is one of 6 in phase 4, and was the 5th registered.
Stanford University’s Pain, Postoperative studies by the year they started, since 2007.
6 of the studies testing ropivacaine in Pain, Postoperative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03230565Stanford UniversityContinuous Infusions vs Scheduled Bolus Infusions | 2026-12 |
| NCT06189781University of California, Los AngelesPain Injection Versus Epidural Anesthesia for Hip Surgery in Pediatric Patients With Cerebral Palsy | 2026-12-30 |
| NCT07099222University of ArizonaEfficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks | 2026-12-31 |
| NCT07704970Huazhong University of Science and TechnologyQLESP Block for Pain Control in Robotic Partial Nephrectomy | 2027-02-28 |
| NCT07853482Maternity Hospital - State Budgetary Institution of the Rostov Region, TaganrogTAP vs. ESP Blocks for Post-Cesarean Analgesia | 2027-05-10 |
Add all 6 to your calendar (.ics) → With an account.
Among the 184 studies testing ropivacaine in Pain, Postoperative, from their registry updates:
Among Stanford University’s 25 in Pain, Postoperative:
This tab as a report to print or save as PDF → With an account.
The goal of the study is to compare continuous infusions and scheduled bolus infusions for peripheral nerve blocks and their effect on post-surgical pain.
Regional anesthetic techniques are an integral part to many anesthetic approaches, providing both intraoperative and postoperative anesthesia and analgesia. Regional anesthesia peripheral nerve blocks have been shown to reduce postoperative pain and improve measures such as opioid requirements and readiness for discharge. By using a catheter technique for continuous peripheral nerve blocks, analgesia can be extended well into post-operative days 2 and 3, further extending these benefits. Historically these catheters have implemented a continuous dosing regimen of local anesthetic, but increasingly there is evidence of improved analgesic outcomes without adverse effects by using a scheduled bolus dosing regimen. Many institutions have implemented this new protocol for catheter dosing. The beneficial effect of scheduled bolus dosing has not been studied in all blocks and all surgical procedures.
The study will consist of three independent arms, each designed to evaluate a different nerve block site: interscalene, adductor canal, and infraclavicular. A total of 60 patients will be enrolled in each arm.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Local anesthetic medication (Ropivacaine 0.2%) is provided at a continuous basal rate.
Drug: Ropivacaine
Local anesthetic medication (Ropivacaine 0.2%) is provided in scheduled, intermittent boluses.
Drug: Ropivacaine
Patient will be given a continuous infusion of local anesthetic.
Also known as: Continuous infusion
Patient will be given a scheduled intermittent bolus of local anesthetic.
Also known as: Bolus Infusion
Post-surgical pain
Pain scores will be collected using a Numeric Rating Scale (NRS) from 0-10, where 0 is the lowest and 10 is the highest pain level.
Time frame: Post-operative day 0, 1, and 2
Opioid consumption
The amount of opioid analgesics (converted to total morphine milligram equivalents) taken by patients will be recorded.
Time frame: Post-operative day 0, 1, and 2
Local anesthetic use
The amount of supplemental local anesthetic boluses self-administered by patients will be recorded (in mL).
Time frame: Post-operative day 1 and 2
Quality of recovery
Quality of recovery will be assessed using a Quality of Recovery (QoR-15) questionnaire. The QoR15 scores range from 0 to 150, where 0 is poor recovery and 150 is excellent recovery.
Time frame: Post-operative day 1 and 2
Evidence of diaphragmatic paralysis
Ability to breathe will be assessed as a part of QoR-15 questionnaire on 11-point scale, where 0 is never being able to breathe easily and 10 is always being able to breathe easily.
Time frame: Post-operative day 1 and 2
Patient satisfaction
Patients will be asked to assess their satisfaction with pain management (Yes/No).
Time frame: Post-operative day 1 and 2
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2018 (actual). Primary completion is estimated for Dec 2026, 102 months after the start.
Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 102 months is above that.
Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ropivacaine